We are designing multi-specific antibodies that enable the pursuit of novel therapeutic strategies for inflammation, cancer, and diseases of high unmet need.
Horgen
Joined November 2019
- Tweets41
- Following179
- Followers141
- Likes36
Congratulations to Tillotts for the successful spin-out of Mage Biologics, which is advancing an anti-TNF therapeutic antibody – discovered at Numab in collaboration with Tillotts – an innovative oral therapy for Ulcerative Colitis. Full press release: bit.ly/43Jmbyw
At #SITC2022, Numab presents Phase 1 dose escalation results of NM21-1480, its anti-PD-L1x4-1BB checkpoint modulator.
Learn more from our team and check out the poster: bit.ly/3gaLw1q
Attending #ProteinSummit in Boston this week? Don’t miss Fabio Spiga’s talk about our MATCH platform this Weds. Meet with Fabio to hear how our platform allows for the generation of a broad variety of first in class multispecific #antibody-based therapeutics. See below for more.
We look forward to attending the Next Generation #ProteinSummit 2022 in Boston. On Sep. 28 at 2:30pm ET, listen to Discovery team member Fabio Spiga's talk: “Combining MATCHs to light the fire of #immunotherapy”: bit.ly/3KjFnKQ
We look forward to attending the Next Generation #ProteinSummit 2022 in Boston. On Sep. 28 at 2:30pm ET, listen to Discovery team member Fabio Spiga's talk: “Combining MATCHs to light the fire of #immunotherapy”: bit.ly/3KjFnKQ
Next week, our CEO David Urech & CFO Roland Helfenstein look forward to attending Morgan Stanley’s 20th Annual Global Healthcare Conference in NYC. Interested in learning more about how Numab is writing the next chapter in cancer #immunotherapy? Contact us: [email protected]
Our team will present a poster at the 31st #EADVCongress in Milan sharing preclinical data on NM26-2198, our novel bispecific antibody simultaneously blocking IL-4, IL-13 & IL-31. View our poster to learn about its potential to treat #atopicdermatitis: bit.ly/3QeBA2Y
We are #hiring! Join our fast-paced and science-driven environment where we value teamwork & excellence. Become closely involved in the entire #drugdiscovery process of developing innovative therapeutics by leveraging our proprietary technology platforms: bit.ly/3Jn7pVz
We're pleased to welcome Wei Xu, MD, PhD, to Numab as our new CSO. A pioneering physician-scientist & true drug hunter, Wei brings over 15 years of experience in immuno-oncology drug development and translational medicine. Learn more about Wei: bit.ly/3GIVe39
Our team will present 2 posters at #AACR22 in New Orleans sharing updates on our #immunooncology programs NM21-1480 and NM28-2746. To learn more, check out our posters linked within our pipeline: bit.ly/3DojO8H
Today we announced a development and license agreement with Ono Pharmaceutical for a multispecific antibody candidate involving a novel immuno-oncology target, generated through a research collaboration between our two companies beginning in 2017: bit.ly/370PHYy
We are thrilled to welcome James Singleton as Numab's General Counsel. James brings over 20 years of #biopharma industry experience serving in various senior legal leadership positions across the U.S. & Europe. Learn more about James: bit.ly/3GIVe39
We expand our partnership with 3SBio’s Sunshine Guojian to develop & commercialize NM28, a potential best-in-class bivalent mesothelin (MSLN)-targeting CD3 T cell engager: bit.ly/347xinZ
Numab presents data on #ROR1-targeting T cell engager NM32-2668 at #SITC2021. Poster download via bit.ly/2Yybpzm. Multi-specifics may have distinct advantages over aROR1 #ADCs [hitting tumor cells irrespective of mitotic activity] or CAR-Ts [being truly off-the-shelf].
Numab will present novel preclinical data on its #ROR1-targeting antibody NM32-2668 at #SITC2021. Check out the SITC website or our website on Friday November 12th to learn more about the tri-specific ROR1xCD3xHSA #TcellEngager.
Meet Numab's VP Head of Protein Engineering & CMC Stefan Warmuth at next week’s #PEGSEurope conference to learn more about Numab's unique technology platform and growing pipeline of multispecifics: bit.ly/3munuyZ
Congratulations to CStone for receiving clearance for their IND application of NM21-1480 (CStone code: CS2006) in China. Numab and CStone signed an exclusive regional licensing agreement for this program covering certain Asian territories in 2019: bit.ly/3lhgLGx
Many thanks to @Ageficom's @SoMaReine for taking the time to recap our recent financing. We intend to grow our team here in #Waedenswil and are always looking for the brightest talent to join us from all regions in Switzerland and abroad. #WeAreHiring - agefi.com/actualites/entrepr…
June is #CancerImmunotherapyMonth. Numab is part of the community driving innovation in #immunotherapy. Learn more about our approach targeting #41bb and #pdl1 with a multispecific antibody and please check out @CancerResearch’s #CIM21 campaign: numab.com/wp-content/themes/…
Our Series C secured in May will boost our lead program in multiple cancer indications. We took the time to explain the concept of targeting #41bb and #pdl1 and why monovalent binding, tumor cell anchoring, and tailored affinities matter in this new video: numab.com/wp-content/themes/…
ALT NM21-1480: A novel tri-specific antibody for oncology. Learn more about its unique mode-of-action
Bi- and multispecific #antibodies have so far contributed just 2 approved therapies to this 100th approval milestone. How will this evolve? Our CEO shared some thoughts in his LinkedIn post while also discussing today's Series C financing: linkedin.com/pulse/pivotal-s…
The FDA approved its 1st monoclonal antibody in 1986, its 50th in 2015 and its 100th last month. For new modalities, this is the timeline to beat. For a look at the first 100 antibodies by target, format and more, see nature.com/articles/d41573-0… in @NatRevDrugDisc
